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Alopecia areata (AA) may represent a CD8þ T cell–
mediated, organ-specific autoimmune disease in
which as yet elusive autoantigens are recognized,
once they become exposed by ectopic major histo-
compatibility complex class I expression by anagen
hair follicles (HFs) that have lost their relative immune
privilege (IP). On this basis, AA research is chiefly
challenged with identifying the autoreactive CD8þ
T cells and their cognate autoantigens as well as key
inducers of HF-IP collapse and ‘‘HF-IP guardians’’ that
prevent and/or can restore IP collapse. However,
natural killer group 2D–positive (NKG2Dþ ) cells (incl.
NK, NKT, and CD8þ T cells) and NKG2D–activating
ligands from the MICA (MHC I–related chain A) family
may also have a key role in AA pathogenesis, as a
massive infiltrate of IFN-g-secreting NKG2Dþ cells
alone suffices to induce the AA phenotype. Therefore,
we speculate that AA may represent a stereotypic, but
distinct HF response pattern to inflammatory insults
associated with HF-IP collapse.
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Over the past two decades, it has been elucidated that the
hair follicle (HF) immune system in mice and man differs
from the general skin immune system in many respects, and
relies on a number of strategies to shield selected (epithelial)
tissue compartments from autoaggressive immune attacks
by generating anatomically circumscribed areas of relative
immune privilege (IP) (Paus et al., 2005). These strategies
include the downregulation of major histocompatibility
complex (MHC) class I and b2 microglobulin molecules in
large parts of the central and proximal HF epithelium, incl.
the bulge and bulb region, the local production of potent
immunosuppressants (e.g., transforming growth factor-b1/2,
a-melanocyte-stimulating hormone) and/or immunoinhi-
bitory ‘‘no danger’’ signals (CD200), and the repression of
intrafollicular antigen-presenting cell and perifollicular natural
killer (NK) cell and mast cell functions (e.g., downregulation
of MHC class II on HF Langerhans cells below the isthmus,
downregulation of NKD2G ligands, upregulation of
macrophage migration inhibitory factor) (Paus et al., 2005;
Meyer et al., 2008; Ito et al., 2008b; Sugawara et al.,
2012). Taken together, this has resurrected the concept
pioneered by R Billingham, who had observed that growing
(anagen) HFs allow melanocyte allotransplants to escape
immune rejection, that HFs enjoy IP (Billingham and Silvers,
1971).
Subsequently, it was proposed that a collapse of the
physiological IP of anagen HFs is a crucial element of alo-
pecia areata (AA) pathogenesis (Paus et al., 1993). Today,
this concept is well-supported by experimental and clinical
evidence (e.g., Gilhar et al., 1998; Kang et al., 2010;
Yoshida et al., 2011; Bertolini et al., 2012; Gilhar et al.,
2012). Namely, although the disease cannot be transferred by
HF autoantibodies, the transfer of CD8þ T cells alone, which
recognize MHC class I–presented autoantigens, suffices to
induce AA lesions in two distinct AA mouse models
(Gilhar et al., 1998; McElwee et al., 2005). Thus, current
evidence favors the pathobiology concept that AA is a
CD8þ T cell–mediated, organ-specific autoimmune disease
in which elusive (e.g., melanogenesis-associated) auto-
antigens are recognized, once they become exposed by
ectopic MHC class I expression by an anagen HF epit-
helium that has lost its relative IP (Paus et al., 1993, 2005;
Gilhar et al., 2012).
Consequently, AA research must strive to identify the
autoreactive CD8þT cells and their cognate autoantigens.
Also, the most important inducers of HF-IP collapse (e.g.,
IFN-g and substance P) and the constitutive ‘‘HF-IP guar-
dians’’ (e.g., a-melanocyte-stimulating hormone, transform-
ing growth factor-b2, calcitonin gene–related peptide, and
vasoactive intestinal peptide) that normally prevent IP
collapse have to be identified (Ito et al., 2004; Peters
et al., 2007; Siebenhaar et al., 2007; Meyer et al., 2009;
Bertolini et al., 2012; Kinori et al., 2012). Therapeutically,
we need to explore how IP guardians and IP–protective
drugs (e.g., FK506, a-melanocyte-stimulating hormone) and/
or antagonists of HF-IP collapse inducers (e.g., NK1 antago-
nists) can best be used to restore a collapsed IP in AA
patients, until it has become possible to tolerize specifi-
cally AA patients against relevant key autoantigens and
related undesired CD8þT cell responses. In future AA
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management, HF-IP restoration may be sensibly comple-
mented by modulating CTLA4 (cytotoxic T lymphocyte
antigen 4)–mediated signaling (Petukhova et al., 2010;
John et al., 2011; Sundberg et al., 2011) and by restoring
defective functions of regulatory CD4þ /CD25þT cells.
This scenario has been complicated by evidence that
natural killer group 2D–positive (NKG2Dþ ) cells (incl. NK,
NKT, and some CD8þT cells) as well as NKG2D–activating
ligands from the MICA (MHC I–related chain A) family may
also have a key role in AA pathogenesis (Ito et al., 2008a, b;
Petukhova et al., 2010). This is supported by genotyping
(Barahmani et al., 2006) and genome-wide association study
evidence (Petukhova et al., 2010; Jagielska et al., 2012).
Interestingly, the injection of peripheral blood mononuclear
cells from healthy individuals that were enriched for
NKG2Dþ or CD56þ cells and activated by IL-2 into
healthy human scalp skin transplanted onto severe-
combined immunodeficient mice can induce a hair loss
pattern that copies the human AA phenotype (Gilhar et al.,
2013). This not only provides the first functional evidence for
the importance of NKG2Dþ cells and/or NKG2D–activating
ligands in AA pathogenesis and HF-IP collapse but also
suggests that a massive infiltrate of IFN-g-secreting NKG2Dþ
cells alone can suffice to induce HF-IP collapse and subse-
quently the characteristic AA phenotype, seemingly indepen-
dent of genetic susceptibility factors and a pre-existing HF-IP
collapse.
This intriguing new humanized mouse of AA (Gilhar et al.,
2013) invites the speculation that AA is not a single disease
entity, but rather a stereotypic, clinically and histologically
distinct HF response pattern to various inflammatory insults
associated with (e.g., IFN-g-induced) HF-IP collapse. Such a
pathogenesis concept is in line with the underappreciated
heterogeneity of AA (see Ikeda, 1965), and integrates the fact
that human HF-IP collapse can be induced by very distinct
stimuli (e.g., IFN-g (Ito et al., 2004), substance P (Peters et al.,
2007), NKG2D/CD56–enriched, IL-2-stimulated peripheral
blood mononuclear cell (Gilhar et al., 2013)) and that the
innate immune system, namely mast cells, may also impact on
AA pathogenesis (Bertolini et al., 2012).
If confirmed, this novel hypothesis of AA pathobiology has
important clinical implications: autoantigen- and T cell spe-
cificity as well as selective gene targeting in future AA would
then be much less important for effective AA management
than suppressing this general, stereotypic HF response pattern
to IP collapse–inducing inflammatory stimuli that we currently
know under the name of ‘‘AA’’. For example, disease
progression may best be halted by nonspecific, but effective
‘‘response pattern suppression’’, whereas disease remission
and hair regrowth may mainly call for ‘‘HF-IP restoration’’
therapy.
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